CME Outfitters Medical Education Fri, 18 Sep 2026 15:03:55 -0400 https://www.cmeoutfitters.com/ af © 2026 CME Outfitters Medical Education yes da5e76b5-e8be-5eb2-9338-986da9b2410b CME Outfitters Medical Education episodic false CMEOcast, a clinical podcast presented by CME Outfitters designed to improve clinician performance and optimize patient outcomes. Learn more about CME Outfitters at www.cmeoutfitters.com.

]]> Buzzsprout (https://www.buzzsprout.com) CME Outfitters Medical Education https://storage.buzzsprout.com/8gb42nn1bmm599ra3vhzgs3d6uju?.jpg CME Outfitters Medical Education https://www.cmeoutfitters.com/ Riding the Waves of Obesity Science – The Phenotype Breakers: Heterogeneity, Signals, and Who Might Benefit from Which Biology Riding the Waves of Obesity Science – The Phenotype Breakers: Heterogeneity, Signals, and Who Might Benefit from Which Biology In this conversation, Andres Acosta, MD, PhD, joins series chair Robert F. Kushner, MD, to explore obesity phenotypes as a framework for individualizing care. Dr. Acosta examines how differences in appetite, satiety, energy expenditure, and eating behavior may help explain the wide variation in treatment response — and offers a candid appraisal of how far the science has come and how far it still has to go, since validated predictors of drug response are not yet established.

As the third of four conversations, this segment turns the series’ theme of heterogeneity into a practical lens. After framing why multiple pathways are needed and exploring the biology of amylin, it asks how clinicians might one day match patient to pathway.

Learn More Here

]]> In this conversation, Andres Acosta, MD, PhD, joins series chair Robert F. Kushner, MD, to explore obesity phenotypes as a framework for individualizing care. Dr. Acosta examines how differences in appetite, satiety, energy expenditure, and eating behavior may help explain the wide variation in treatment response — and offers a candid appraisal of how far the science has come and how far it still has to go, since validated predictors of drug response are not yet established.

As the third of four conversations, this segment turns the series’ theme of heterogeneity into a practical lens. After framing why multiple pathways are needed and exploring the biology of amylin, it asks how clinicians might one day match patient to pathway.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19828525 Fri, 18 Sep 2026 15:00:00 -0400 2116 full false Extraintestinal Manifestations in IBD — Screening, Referral Triggers, and Multidisciplinary Care Pathways Extraintestinal Manifestations in IBD — Screening, Referral Triggers, and Multidisciplinary Care Pathways In the third activity of this CMEO podcast series, expert faculty will assist learners to recognize common and clinically significant extraintestinal manifestations associated with IBD, incorporate practical screening approaches into routine clinical workflows, and implement multidisciplinary care strategies for patients with systemic disease involvement.

Learn More Here

]]> In the third activity of this CMEO podcast series, expert faculty will assist learners to recognize common and clinically significant extraintestinal manifestations associated with IBD, incorporate practical screening approaches into routine clinical workflows, and implement multidisciplinary care strategies for patients with systemic disease involvement.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19791748 Fri, 11 Sep 2026 14:00:00 -0400 2730 full false Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.

Learn More Here

]]> In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19719650 Fri, 28 Aug 2026 16:00:00 -0400 1502 full false Riding the Waves of Obesity Science – Amylin at a Glance: A Mechanistic Map of a Systems Satiety Signal Riding the Waves of Obesity Science – Amylin at a Glance: A Mechanistic Map of a Systems Satiety Signal In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.

Learn More Here

]]> In this second CMEO Snack of the Riding the Waves of Obesity Science series, amylin researcher Matthew R. Hayes, PhD joins moderator Robert F. Kushner, MD for a focused, practical conversation that turns amylin from a half‑remembered footnote into working clinical knowledge; what amylin actually does, how its calcitonin‑receptor/receptor activity-modifying protein (RAMP) biology shapes today’s drug classes, and why its signal complements rather than duplicates glucagon-like peptide-1 (GLP‑1). Designed for physicians, nurse practitioners, physician associates, and pharmacists across obesity medicine, endocrinology, primary care, and cardiometabolic practice, this activity will help you read the emerging science with a sharper eye and be ready for the amylin‑based therapies that may be on the horizon.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19719642 Fri, 28 Aug 2026 16:00:00 -0400 1363 full false Case Closed? Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects Case Closed? Diagnosing Idiopathic Hypersomnia Beyond the Usual Suspects Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and frustrating atop the disease burden itself. Overlapping symptoms with conditions such as depression, anxiety, and cardiovascular disease often obscure the true cause, while distinguishing IH itself from narcoleptic sleep disorders can be equally complex. As a rare condition, IH can leave patients feeling isolated and misunderstood while enduring an unpredictable constellation of symptoms. By sharpening diagnostic precision and fostering collaboration across multidisciplinary teams, clinicians can unlock new opportunities in the therapeutic landscape to deliver personalized, patient-centered care that addresses the unique challenges of living with IH.

This fast-paced and highly interactive recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply guideline-recommended diagnostic criteria and comprehensive assessments into practice when there is clinical suspicion of IH to improve early and accurate diagnosis.

Learn More Here

]]> Idiopathic hypersomnia (IH) is a life-disrupting condition characterized by excessive daytime sleepiness (EDS) that makes waking up a daily struggle, limits productivity, and erodes overall quality of life. For many patients with IH, the journey to diagnosis is long and frustrating atop the disease burden itself. Overlapping symptoms with conditions such as depression, anxiety, and cardiovascular disease often obscure the true cause, while distinguishing IH itself from narcoleptic sleep disorders can be equally complex. As a rare condition, IH can leave patients feeling isolated and misunderstood while enduring an unpredictable constellation of symptoms. By sharpening diagnostic precision and fostering collaboration across multidisciplinary teams, clinicians can unlock new opportunities in the therapeutic landscape to deliver personalized, patient-centered care that addresses the unique challenges of living with IH.

This fast-paced and highly interactive recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply guideline-recommended diagnostic criteria and comprehensive assessments into practice when there is clinical suspicion of IH to improve early and accurate diagnosis.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19699831 Tue, 25 Aug 2026 09:00:00 -0400 6397 full false Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team Unveiling HER2-Low and Ultralow Expression in mBC: Implications for the Multidisciplinary Care Team The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.

In the first activity of this EfficientCME webcast series, two leading breast oncologists and a partnering pathologist examine the evolving understanding of HER2 biology and explain why new testing and interpretation methods for HER2-low and ultralow expression in mBC are emerging. Through expert discussion, they explore key evidence driving this shift and what it means for clinical practice moving forward.

Learn More Here

]]> The emergence of HER2-low and ultralow classifications in mBC (mBC) is reshaping treatment options, offering new hope for patients who were once considered ineligible for targeted therapy. Yet many clinicians face uncertainty about how to appropriately define these new phenotypes and apply emerging evidence to routine practice. With antibody-drug conjugates (ADCs) transforming the treatment landscape, today’s oncology and pathology teams need practical guidance that connects diagnostic precision with therapeutic decision-making to improve patient outcomes.

In the first activity of this EfficientCME webcast series, two leading breast oncologists and a partnering pathologist examine the evolving understanding of HER2 biology and explain why new testing and interpretation methods for HER2-low and ultralow expression in mBC are emerging. Through expert discussion, they explore key evidence driving this shift and what it means for clinical practice moving forward.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19678295 Thu, 20 Aug 2026 16:00:00 -0400 1933 full false Fibrosis in IBD — Pathogenesis, Risk Stratification, and Objective Monitoring Fibrosis in IBD — Pathogenesis, Risk Stratification, and Objective Monitoring Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing patients at risk for fibrotic progression and inconsistently apply objective monitoring and management strategies until complications have already developed. In addition, evolving insights into the biologic mechanisms driving chronic tissue remodeling and emerging therapeutic approaches targeting these pathways have not yet been fully integrated into routine clinical practice. This podcast, designed for gastroenterologists, GI fellows, physician associates, nurse practitioners, nurses, and pharmacists will strengthen understanding of fibrosis pathogenesis, improve risk stratification and monitoring practices, and support earlier, outcomes-focused intervention in patients with IBD.

In the second activity of this CMEO podcast series, expert faculty will assist learners to examine the biologic pathways involved in IBD-related fibrosis, recognize clinical characteristics and disease patterns associated with fibrotic progression, and implement objective monitoring and management approaches to evaluate ongoing structural bowel damage.

Learn More Here

]]> Fibrosis remains one of the greatest unmet needs in inflammatory bowel disease (IBD), contributing to irreversible structural bowel damage, complications, and long-term morbidity despite advances in anti-inflammatory therapies. Many gastroenterologists and multidisciplinary gastrointestinal (GI) care teams lack confidence in recognizing patients at risk for fibrotic progression and inconsistently apply objective monitoring and management strategies until complications have already developed. In addition, evolving insights into the biologic mechanisms driving chronic tissue remodeling and emerging therapeutic approaches targeting these pathways have not yet been fully integrated into routine clinical practice. This podcast, designed for gastroenterologists, GI fellows, physician associates, nurse practitioners, nurses, and pharmacists will strengthen understanding of fibrosis pathogenesis, improve risk stratification and monitoring practices, and support earlier, outcomes-focused intervention in patients with IBD.

In the second activity of this CMEO podcast series, expert faculty will assist learners to examine the biologic pathways involved in IBD-related fibrosis, recognize clinical characteristics and disease patterns associated with fibrotic progression, and implement objective monitoring and management approaches to evaluate ongoing structural bowel damage.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19673243 Wed, 19 Aug 2026 16:00:00 -0400 3540 full false Webcast: CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes Webcast: CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes In this CME Outfitters Engage the Experts recorded session, the community-based expert faculty from the Project ECHO® series will provide a comprehensive summary of key insights from the five-session CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes – A Project ECHO® Initiative series. Topics will include the clinical heterogeneity and pathophysiology of CIDP and the significance of IgG autoantibodies in its development, guideline-recommended diagnostic criteria to identify patients with CIDP, current and emerging treatment options including limitations of standard therapies and appropriate integration of novel agents into practice, and how to use collaborative care strategies to enhance long-term outcomes and quality of life for individuals with CIDP.

Learn More Here

]]> In this CME Outfitters Engage the Experts recorded session, the community-based expert faculty from the Project ECHO® series will provide a comprehensive summary of key insights from the five-session CIDP Masterclass: Early Diagnosis, Emerging Options, Better Outcomes – A Project ECHO® Initiative series. Topics will include the clinical heterogeneity and pathophysiology of CIDP and the significance of IgG autoantibodies in its development, guideline-recommended diagnostic criteria to identify patients with CIDP, current and emerging treatment options including limitations of standard therapies and appropriate integration of novel agents into practice, and how to use collaborative care strategies to enhance long-term outcomes and quality of life for individuals with CIDP.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19648123 Fri, 14 Aug 2026 14:00:00 -0400 4571 full false Cleared for Takeoff: An All-Hands-on Deck Approach to Building Confidence and Competence in S1P Receptor Modulator Initiation for Ulcerative Colitis Cleared for Takeoff: An All-Hands-on Deck Approach to Building Confidence and Competence in S1P Receptor Modulator Initiation for Ulcerative Colitis For people living with ulcerative colitis (UC), cycles of remission and relapse can disrupt daily life and complicate long-term management. Sphingosine-1-phosphate receptor modulators (S1Prms) are a new class of targeted oral therapies with the potential to reduce colonic inflammation and improve outcomes. Initiating them follows a clear, well-defined pathway: a focused set of baseline assessments supports safe, confident use and helps teams match the right patients to therapy. With practical, evidence-based education, clinicians and multidisciplinary care teams can bring S1Prms into routine practice with confidence.

This CME Outfitters recorded webcast makes that pathway clear and approachable, with expert faculty modeling how to fold baseline assessment into real-world workflows. It brings together perspectives from across the care team, including academic experts, community providers, gastroenterology, cardiology, and nurse practitioners, so the guidance translates for all providers.

Learn More Here

]]> For people living with ulcerative colitis (UC), cycles of remission and relapse can disrupt daily life and complicate long-term management. Sphingosine-1-phosphate receptor modulators (S1Prms) are a new class of targeted oral therapies with the potential to reduce colonic inflammation and improve outcomes. Initiating them follows a clear, well-defined pathway: a focused set of baseline assessments supports safe, confident use and helps teams match the right patients to therapy. With practical, evidence-based education, clinicians and multidisciplinary care teams can bring S1Prms into routine practice with confidence.

This CME Outfitters recorded webcast makes that pathway clear and approachable, with expert faculty modeling how to fold baseline assessment into real-world workflows. It brings together perspectives from across the care team, including academic experts, community providers, gastroenterology, cardiology, and nurse practitioners, so the guidance translates for all providers.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19647947 Fri, 14 Aug 2026 14:00:00 -0400 3901 full false Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current Riding the Waves of Obesity Science – A Multi-Pathway Rationale for the Next Therapeutic Current In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.

Learn More Here

]]> In this opening conversation, Lee M. Kaplan, MD, PhD, joins series chair Robert F. Kushner, MD, to make a deceptively simple case: because no single mechanism drives obesity in every patient, no single mechanism will treat it in every patient. Drawing on the logic clinicians already apply to hypertension and diabetes, Dr. Kaplan explains why a heterogeneous disease demands multiple, complementary treatment pathways — and why amylin represents a genuinely new “current” in that effort.

In the first activity of this CMEO Snack series, expert faculty will set the stage for the series: the biology of amylin, the promise of phenotype-guided care, and the emerging trial data that follow across three more expert conversations. Short, practical, and forward-looking — an essential primer for any clinician preparing for the next era of obesity care.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19642363 Thu, 13 Aug 2026 10:00:00 -0400 1502 full false Beyond Symptoms — The Hidden Burden of IBD and the Future of Disease Modification Beyond Symptoms — The Hidden Burden of IBD and the Future of Disease Modification Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often focus primarily on luminal inflammation, with limited integration of fibrosis, extraintestinal manifestations (EIMs), and cumulative inflammatory burden into long-term treatment planning and disease modification strategies. As emerging scientific concepts and therapeutic approaches increasingly aim to alter the trajectory of IBD progression, clinicians such as gastroenterologists, GI fellows, physician associates, nurse practitioners, nurses, nurses, and pharmacists require a deeper understanding of how chronic inflammation contributes to irreversible intestinal and systemic consequences beyond symptoms alone.

In the first activity of this CMEO podcast series, expert faculty will assist learners to recognize fibrosis and extraintestinal manifestations as interconnected complications of chronic IBD, examine the role of cumulative inflammation in driving long-term structural and systemic disease progression, and apply emerging disease-modification concepts intended to improve long-term patient outcomes.

Learn More Here

]]> Although treatment advances in inflammatory bowel disease (IBD) have improved symptom control, many patients continue to experience progressive structural bowel damage and systemic complications that are not adequately addressed in routine care. Gastroenterologists and multidisciplinary gastrointestinal (GI) care teams often focus primarily on luminal inflammation, with limited integration of fibrosis, extraintestinal manifestations (EIMs), and cumulative inflammatory burden into long-term treatment planning and disease modification strategies. As emerging scientific concepts and therapeutic approaches increasingly aim to alter the trajectory of IBD progression, clinicians such as gastroenterologists, GI fellows, physician associates, nurse practitioners, nurses, nurses, and pharmacists require a deeper understanding of how chronic inflammation contributes to irreversible intestinal and systemic consequences beyond symptoms alone.

In the first activity of this CMEO podcast series, expert faculty will assist learners to recognize fibrosis and extraintestinal manifestations as interconnected complications of chronic IBD, examine the role of cumulative inflammation in driving long-term structural and systemic disease progression, and apply emerging disease-modification concepts intended to improve long-term patient outcomes.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19616087 Fri, 07 Aug 2026 16:00:00 -0400 2829 full false Rethinking Suppression: GnRH Antagonists and Contemporary Endometriosis Management Rethinking Suppression: GnRH Antagonists and Contemporary Endometriosis Management Endometriosis is a chronic inflammatory condition that remains underrecognized and undertreated, leaving many individuals of reproductive age with daily pain and disruption. Patients often face preference‑sensitive decisions about pain management, contraception, and fertility without clear guidance, frequently after years‑long diagnostic delays. Although gonadotropin‑releasing hormone (GnRH) antagonists and other contemporary therapies have expanded options for endometriosis‑associated pain, many clinicians remain anchored to NSAIDs and combined hormonal contraceptives, leading to suboptimal selection and sequencing of non‑surgical treatments. Community clinicians, particularly in underserved settings, face additional challenges due to limited resources and specialty support. By equipping clinicians with cutting-edge education, we can modernize and optimize treatment for a patient population that has waited far too long for compassionate care.

In this CME Outfitters Snack, expert faculty will demonstrate evidence‑based use of GnRH antagonists within non‑surgical management, including patient selection, dosing, monitoring, and positioning. Faculty will model how to individualize therapy by integrating patient goals, clinical characteristics, and current evidence into tailored medical plans that strengthen therapeutic sequencing and shared decision‑making.

Learn More Here

]]> Endometriosis is a chronic inflammatory condition that remains underrecognized and undertreated, leaving many individuals of reproductive age with daily pain and disruption. Patients often face preference‑sensitive decisions about pain management, contraception, and fertility without clear guidance, frequently after years‑long diagnostic delays. Although gonadotropin‑releasing hormone (GnRH) antagonists and other contemporary therapies have expanded options for endometriosis‑associated pain, many clinicians remain anchored to NSAIDs and combined hormonal contraceptives, leading to suboptimal selection and sequencing of non‑surgical treatments. Community clinicians, particularly in underserved settings, face additional challenges due to limited resources and specialty support. By equipping clinicians with cutting-edge education, we can modernize and optimize treatment for a patient population that has waited far too long for compassionate care.

In this CME Outfitters Snack, expert faculty will demonstrate evidence‑based use of GnRH antagonists within non‑surgical management, including patient selection, dosing, monitoring, and positioning. Faculty will model how to individualize therapy by integrating patient goals, clinical characteristics, and current evidence into tailored medical plans that strengthen therapeutic sequencing and shared decision‑making.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19509572 Fri, 17 Jul 2026 14:00:00 -0400 2764 full false Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Inhibitors Reimagining Management of Generalized Myasthenia Gravis: A Focus on FcRn Inhibitors Generalized myasthenia gravis (gMG) is a chronic neuromuscular disorder that results from destruction of the neuromuscular junction by pathogenic autoantibodies, partially through the actions of the neonatal Fc receptor (FcRn). Traditional therapies only partially alleviate the heavy disease burden and episodic exacerbations characteristic of gMG. In recent years, FcRn antagonists have shown great promise across broad gMG populations. Clinicians in collaboration with a multidisciplinary care team must understand the potential benefits of FcRn agonists and update best practices to care for patients with gMG.

In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.


Learn More Here

]]> Generalized myasthenia gravis (gMG) is a chronic neuromuscular disorder that results from destruction of the neuromuscular junction by pathogenic autoantibodies, partially through the actions of the neonatal Fc receptor (FcRn). Traditional therapies only partially alleviate the heavy disease burden and episodic exacerbations characteristic of gMG. In recent years, FcRn antagonists have shown great promise across broad gMG populations. Clinicians in collaboration with a multidisciplinary care team must understand the potential benefits of FcRn agonists and update best practices to care for patients with gMG.

In this CME Outfitters recorded webcast, expert faculty will discuss the role of FcRn in the pathogenesis of gMG, evaluate the safety and efficacy of FcRn antagonists for the treatment of gMG, and provide expert guidance on how to identify patients with gMG who may be appropriate candidates for treatment with FcRn antagonists. Finally, they will model development of optimized and individualized treatment plans for patients with gMG receiving FcRn antagonists, providing learners with key skills to bring back to clinical practice.


Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19492278 Tue, 14 Jul 2026 08:00:00 -0400 3286 full false Risk Stratification in Hospitalized SARS-CoV-2 Patients Risk Stratification in Hospitalized SARS-CoV-2 Patients Comprehensive patient assessment and accurate risk stratification are cornerstones of effective inpatient management of SARS-CoV-2. However, the absence of a clear consensus on how to categorize patients by risk—and the limited availability of validated, reliable scoring systems—continues to challenge clinical decision-making. With therapeutic choices often hinging on disease severity and progression risk, healthcare professionals face uncertainty in selecting the most appropriate tools to inform treatment. This educational initiative will offer guidance on navigating the strengths and limitations of existing risk prediction models as well as their application across varied clinical scenarios to enhance individualized patient care and outcomes.

In this third installment of a CME Outfitters Snack Series, expert faculty will evaluate clinically supported risk stratification tools and clinical indicators to identify hospitalized patients more accurately with SARS-CoV-2 infection who are at increased risk for progression to severe disease.

Learn More Here

]]> Comprehensive patient assessment and accurate risk stratification are cornerstones of effective inpatient management of SARS-CoV-2. However, the absence of a clear consensus on how to categorize patients by risk—and the limited availability of validated, reliable scoring systems—continues to challenge clinical decision-making. With therapeutic choices often hinging on disease severity and progression risk, healthcare professionals face uncertainty in selecting the most appropriate tools to inform treatment. This educational initiative will offer guidance on navigating the strengths and limitations of existing risk prediction models as well as their application across varied clinical scenarios to enhance individualized patient care and outcomes.

In this third installment of a CME Outfitters Snack Series, expert faculty will evaluate clinically supported risk stratification tools and clinical indicators to identify hospitalized patients more accurately with SARS-CoV-2 infection who are at increased risk for progression to severe disease.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476451 Fri, 10 Jul 2026 16:00:00 -0400 1472 full false Unraveling the Complexities of cUTI Care: Modernizing cUTI Care with the 2025 IDSA and EAU Updates Unraveling the Complexities of cUTI Care: Modernizing cUTI Care with the 2025 IDSA and EAU Updates Complicated urinary tract infections (cUTIs) represent an important and growing challenge in clinical practice, affecting individual patients’ health and quality of life while exerting a substantial burden on the healthcare system. Despite being common, these infections are underrecognized. The July 2025 Infectious Diseases Society of America (IDSA) and concurrent EAU guidelines have redefined the classification of UTIs, emphasizing severity, resistance risk factors, and patient-specific considerations, allowing for more precise diagnosis and treatment selection. It is, therefore, imperative for clinicians and care systems to update their approach to diagnosing, treating, and transitioning care for patients with cUTI.

In this CME Outfitters recorded webcast, expert faculty will guide learners through the burden of cUTI on individual patients and the broader healthcare system, identify opportunities for improved care and outcomes for patients with cUTI through the utilization of up-to-date guidelines and new and emerging antibiotic therapies, and help ensure that patients with cUTI are treated in the appropriate healthcare setting and are transitioned seamlessly between inpatient and outpatient care.

Learn More Here

]]> Complicated urinary tract infections (cUTIs) represent an important and growing challenge in clinical practice, affecting individual patients’ health and quality of life while exerting a substantial burden on the healthcare system. Despite being common, these infections are underrecognized. The July 2025 Infectious Diseases Society of America (IDSA) and concurrent EAU guidelines have redefined the classification of UTIs, emphasizing severity, resistance risk factors, and patient-specific considerations, allowing for more precise diagnosis and treatment selection. It is, therefore, imperative for clinicians and care systems to update their approach to diagnosing, treating, and transitioning care for patients with cUTI.

In this CME Outfitters recorded webcast, expert faculty will guide learners through the burden of cUTI on individual patients and the broader healthcare system, identify opportunities for improved care and outcomes for patients with cUTI through the utilization of up-to-date guidelines and new and emerging antibiotic therapies, and help ensure that patients with cUTI are treated in the appropriate healthcare setting and are transitioned seamlessly between inpatient and outpatient care.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476443 Fri, 10 Jul 2026 16:00:00 -0400 3466 full false Improving Quality of Life and Care in Lennox-Gastaut Syndrome: Best Practices for Collaborative, Family- and Patient-Centered Management Improving Quality of Life and Care in Lennox-Gastaut Syndrome: Best Practices for Collaborative, Family- and Patient-Centered Management Lennox-Gastaut syndrome (LGS) affects every aspect of patients’ and caregivers’ lives, often far beyond seizures alone. Families face a fragmented system, where pediatric and adult care are poorly aligned, social services are hard to navigate, and long-term planning is unsupported. Younger patients with LGS are frequently misunderstood in emergency and school settings, while older patients may experience isolation and lack of access to appropriate adult services. These gaps contribute to caregiver fatigue, emotional distress, and a loss of confidence in support systems. Clinicians and multidisciplinary care teams require best-in-class education to address these gaps, meet the early and lifelong needs of individuals with LGS, and restore confidence in care.

In this CME Outfitters recorded webcast, expert faculty will explore comorbidities and quality-of-life concerns that impact individuals with LGS and their caregivers. The activity will highlight team-based strategies to support long-term planning and successful transitions from pediatric to adult care.

Learn More Here

]]> Lennox-Gastaut syndrome (LGS) affects every aspect of patients’ and caregivers’ lives, often far beyond seizures alone. Families face a fragmented system, where pediatric and adult care are poorly aligned, social services are hard to navigate, and long-term planning is unsupported. Younger patients with LGS are frequently misunderstood in emergency and school settings, while older patients may experience isolation and lack of access to appropriate adult services. These gaps contribute to caregiver fatigue, emotional distress, and a loss of confidence in support systems. Clinicians and multidisciplinary care teams require best-in-class education to address these gaps, meet the early and lifelong needs of individuals with LGS, and restore confidence in care.

In this CME Outfitters recorded webcast, expert faculty will explore comorbidities and quality-of-life concerns that impact individuals with LGS and their caregivers. The activity will highlight team-based strategies to support long-term planning and successful transitions from pediatric to adult care.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476388 Fri, 10 Jul 2026 16:00:00 -0400 4468 full false Addressing Unmet Needs in Retinal Disease: Pairing Therapeutic Advances with Personalized Care Addressing Unmet Needs in Retinal Disease: Pairing Therapeutic Advances with Personalized Care Retinal disease includes a wide array of conditions affecting the retina that, if not detected and treated early, can significantly impair quality of life, independence, and mobility while increasing the risk of accidental injury. These conditions also impose a substantial socioeconomic burden through health care costs, lost productivity, and disability. Persistent gaps in care and treatment contribute to ongoing disease burden, underscoring the need for continued advances in therapies, guidelines, and clinician education to improve outcomes and reduce treatment burden for patients with retinal disease.

In this CME Outfitters recorded webcast, expert faculty will discuss guideline-recommended approaches to the diagnosis and management of retinal disease, explore strategies for developing individualized treatment plans that address patient needs and access barriers, and examine the mechanistic role of blood–retinal barrier dysfunction as the scientific rationale for emerging therapies. The webcast will also feature patient interviews.

Learn More Here

]]> Retinal disease includes a wide array of conditions affecting the retina that, if not detected and treated early, can significantly impair quality of life, independence, and mobility while increasing the risk of accidental injury. These conditions also impose a substantial socioeconomic burden through health care costs, lost productivity, and disability. Persistent gaps in care and treatment contribute to ongoing disease burden, underscoring the need for continued advances in therapies, guidelines, and clinician education to improve outcomes and reduce treatment burden for patients with retinal disease.

In this CME Outfitters recorded webcast, expert faculty will discuss guideline-recommended approaches to the diagnosis and management of retinal disease, explore strategies for developing individualized treatment plans that address patient needs and access barriers, and examine the mechanistic role of blood–retinal barrier dysfunction as the scientific rationale for emerging therapies. The webcast will also feature patient interviews.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476366 Fri, 10 Jul 2026 16:00:00 -0400 3577 full false Breaking Barriers – Implementing Status-Neutral HIV Screening and Prevention for All Breaking Barriers – Implementing Status-Neutral HIV Screening and Prevention for All Despite significant strides in HIV prevention, global incidence rates remain high, especially among underserved populations, due in part to persistent barriers in routine screening and access to pre-exposure prophylaxis (PrEP). Many healthcare professionals across the globe, including HIV and infectious disease specialists, primary care clinicians, and pharmacists, lack adequate training on implementing status-neutral screening strategies and integrating newer PrEP modalities, such as long-acting injectables, into practice. Cultural stigma, low health literacy, and system-level workflow challenges further hinder global prevention efforts and widen care disparities. Education is needed to equip clinicians worldwide with the tools, knowledge, and confidence to adopt status-neutral HIV prevention approaches that are culturally sensitive, patient-centered, and aligned with current guidelines.

In the first activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss how to develop tailored strategies that address barriers to status-neutral HIV screening and effective HIV prevention strategies such as PrEP.

Learn More Here

]]> Despite significant strides in HIV prevention, global incidence rates remain high, especially among underserved populations, due in part to persistent barriers in routine screening and access to pre-exposure prophylaxis (PrEP). Many healthcare professionals across the globe, including HIV and infectious disease specialists, primary care clinicians, and pharmacists, lack adequate training on implementing status-neutral screening strategies and integrating newer PrEP modalities, such as long-acting injectables, into practice. Cultural stigma, low health literacy, and system-level workflow challenges further hinder global prevention efforts and widen care disparities. Education is needed to equip clinicians worldwide with the tools, knowledge, and confidence to adopt status-neutral HIV prevention approaches that are culturally sensitive, patient-centered, and aligned with current guidelines.

In the first activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss how to develop tailored strategies that address barriers to status-neutral HIV screening and effective HIV prevention strategies such as PrEP.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476311 Fri, 10 Jul 2026 15:00:00 -0400 2890 full false Transforming MS Care: Advanced Strategies in Multiple Sclerosis Management Transforming MS Care: Advanced Strategies in Multiple Sclerosis Management Multiple sclerosis (MS) is a chronic, immune-mediated disease in which early, individualized disease-modifying therapy (DMT) can reduce disease activity, delay disability progression, and preserve quality of life. As therapeutic options expand—particularly multiple anti-CD20 therapies with different dosing schedules, administration routes, and safety considerations—clinicians must accurately interpret trial and real-world data, weigh risk–benefit trade-offs, and align recommendations with patient goals. Inconsistent application of evidence-based MS management guidelines and variability in monitoring practices can contribute to suboptimal therapeutic outcomes, especially in older and pediatric patients, whose physiological and social considerations may affect tolerability, adherence, and long-term disease control.

In this CMEO BriefCase, expert faculty will walk learners through a real-world case, stopping for strategic discussions on the assessment of data on available anti-CD20 therapies to make appropriate recommendations for patients with MS, utilization of evidence-based guidelines for MS management to optimize treatment selection and monitor therapeutic outcomes, and the development of tailored MS treatment plans to address the unique physiological and social needs of older and pediatric patients.

Learn More Here 

]]> Multiple sclerosis (MS) is a chronic, immune-mediated disease in which early, individualized disease-modifying therapy (DMT) can reduce disease activity, delay disability progression, and preserve quality of life. As therapeutic options expand—particularly multiple anti-CD20 therapies with different dosing schedules, administration routes, and safety considerations—clinicians must accurately interpret trial and real-world data, weigh risk–benefit trade-offs, and align recommendations with patient goals. Inconsistent application of evidence-based MS management guidelines and variability in monitoring practices can contribute to suboptimal therapeutic outcomes, especially in older and pediatric patients, whose physiological and social considerations may affect tolerability, adherence, and long-term disease control.

In this CMEO BriefCase, expert faculty will walk learners through a real-world case, stopping for strategic discussions on the assessment of data on available anti-CD20 therapies to make appropriate recommendations for patients with MS, utilization of evidence-based guidelines for MS management to optimize treatment selection and monitor therapeutic outcomes, and the development of tailored MS treatment plans to address the unique physiological and social needs of older and pediatric patients.

Learn More Here 

]]> CME Outfitters Medical Education Buzzsprout-19476166 Fri, 10 Jul 2026 15:00:00 -0400 3780 full false Expanding Access – Optimizing Use of Long-Acting Injectable PrEP Expanding Access – Optimizing Use of Long-Acting Injectable PrEP Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) represents a major advancement in HIV prevention, offering new opportunities to support adherence and reduce transmission, yet its optimal use remains underrealized across global healthcare settings. Many HIV/infectious disease specialists, primary care clinicians, and pharmacists worldwide lack clarity on patient selection criteria, initiation and transition strategies, and long-term monitoring requirements for LAI PrEP. These gaps, coupled with limited training and implementation barriers such as workflow challenges and stigma, restrict access for populations that could benefit most. Targeted education is needed to equip providers across the globe with the practical knowledge and confidence to integrate LAI PrEP into prevention efforts and expand access to effective, individualized HIV care.

In the third activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss the latest information on LAI PrEP options for HIV, including expanding access for optimal patient selection, strategies for transitioning to an LAI and considerations for monitoring.

Learn More Here

]]> Long-acting injectable (LAI) pre-exposure prophylaxis (PrEP) represents a major advancement in HIV prevention, offering new opportunities to support adherence and reduce transmission, yet its optimal use remains underrealized across global healthcare settings. Many HIV/infectious disease specialists, primary care clinicians, and pharmacists worldwide lack clarity on patient selection criteria, initiation and transition strategies, and long-term monitoring requirements for LAI PrEP. These gaps, coupled with limited training and implementation barriers such as workflow challenges and stigma, restrict access for populations that could benefit most. Targeted education is needed to equip providers across the globe with the practical knowledge and confidence to integrate LAI PrEP into prevention efforts and expand access to effective, individualized HIV care.

In the third activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss the latest information on LAI PrEP options for HIV, including expanding access for optimal patient selection, strategies for transitioning to an LAI and considerations for monitoring.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476141 Fri, 10 Jul 2026 15:00:00 -0400 2773 full false Staying Current – Navigating the Latest Advances in PrEP Options Staying Current – Navigating the Latest Advances in PrEP Options As HIV prevention strategies continue to evolve, healthcare professionals across the globe face persistent knowledge gaps in evaluating and integrating the latest pre-exposure prophylaxis (PrEP) options, including long-acting injectable (LAI) agents. Many clinicians worldwide remain unfamiliar with the mechanisms of action (MOA), tolerability and safety profiles, and administration considerations associated with newer PrEP formulations, limiting their ability to tailor prevention strategies to specific patient needs. This lack of up-to-date training contributes to underutilization of PrEP, missed prevention opportunities, and ongoing disparities in care delivery. Education is needed for HIV/infectious disease (ID) specialists, primary care providers, pharmacists, and other frontline clinicians across the globe to strengthen their understanding of emerging PrEP options and improve evidence-based, patient-centered HIV prevention worldwide.

In the second activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss the latest information on PrEP options for HIV, including efficacy, safety, MOAs and modes of administration.

Learn More Here

]]> As HIV prevention strategies continue to evolve, healthcare professionals across the globe face persistent knowledge gaps in evaluating and integrating the latest pre-exposure prophylaxis (PrEP) options, including long-acting injectable (LAI) agents. Many clinicians worldwide remain unfamiliar with the mechanisms of action (MOA), tolerability and safety profiles, and administration considerations associated with newer PrEP formulations, limiting their ability to tailor prevention strategies to specific patient needs. This lack of up-to-date training contributes to underutilization of PrEP, missed prevention opportunities, and ongoing disparities in care delivery. Education is needed for HIV/infectious disease (ID) specialists, primary care providers, pharmacists, and other frontline clinicians across the globe to strengthen their understanding of emerging PrEP options and improve evidence-based, patient-centered HIV prevention worldwide.

In the second activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss the latest information on PrEP options for HIV, including efficacy, safety, MOAs and modes of administration.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476129 Fri, 10 Jul 2026 15:00:00 -0400 2552 full false A CaseWise™ Initiative – Mission Possible: Matching Treatment Goals of Patients and Providers in IBD in Clinical Practice A CaseWise™ Initiative – Mission Possible: Matching Treatment Goals of Patients and Providers in IBD in Clinical Practice Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While gastroenterologists and other members of the care team are increasingly aware of new efficacy and safety data, many report uncertainty in selecting, sequencing, and communicating these treatment choices in ways that align with patient preferences, quality-of-life priorities, and long-term disease control.

This fast-paced recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply the latest IL-23 inhibitor data, enhance communication and shared decision-making, and deliver truly patient-centered IBD care.

Learn More Here

]]> Despite major advances in inflammatory bowel disease (IBD) management, real-world data show that many patients continue to experience suboptimal outcomes due to misaligned treatment goals, therapeutic inertia, and limited integration of novel therapies, particularly IL-23 inhibitors—into individualized care plans. While gastroenterologists and other members of the care team are increasingly aware of new efficacy and safety data, many report uncertainty in selecting, sequencing, and communicating these treatment choices in ways that align with patient preferences, quality-of-life priorities, and long-term disease control.

This fast-paced recorded CaseWise™ symposium from CME Outfitters will bring real-world clinical decision-making to life. Through dynamic patient cases, learners will compare their treatment choices to those of leading experts, peers in the room, providers in the community, patients themselves, and even AI-based insights. Learners will see how evidence translates into practice, what doesn’t, and why. Designed to challenge assumptions and sharpen strategy, this immersive format empowers clinicians to immediately apply the latest IL-23 inhibitor data, enhance communication and shared decision-making, and deliver truly patient-centered IBD care.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19476123 Fri, 10 Jul 2026 15:00:00 -0400 7467 full false Partnering for Success – Patient Engagement and PrEP Adherence Strategies Partnering for Success – Patient Engagement and PrEP Adherence Strategies Across diverse global settings, patient engagement and sustained adherence remain major challenges in HIV prevention, particularly with pre-exposure prophylaxis (PrEP). Barriers such as insufficient provider training in communication strategies, in addition to broader issues such as stigma, limited health literacy, and cultural norms, often undermine initiation and long-term use of PrEP. Healthcare professionals, including HIV/infectious disease (ID) specialists, primary care providers, nurses, and pharmacists, need practical education on how to build trust, tailor engagement, and co-create adherence plans that reflect patients’ lived experiences and preferences. Empowering clinicians with effective, culturally sensitive strategies for patient-centered care is essential to closing gaps in PrEP uptake and achieving meaningful reductions in HIV transmission worldwide.

In the fourth activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss using patient engagement and working with patients collaboratively to promote worldwide PrEP initiation and adherence strategies.


Learn More Here

]]> Across diverse global settings, patient engagement and sustained adherence remain major challenges in HIV prevention, particularly with pre-exposure prophylaxis (PrEP). Barriers such as insufficient provider training in communication strategies, in addition to broader issues such as stigma, limited health literacy, and cultural norms, often undermine initiation and long-term use of PrEP. Healthcare professionals, including HIV/infectious disease (ID) specialists, primary care providers, nurses, and pharmacists, need practical education on how to build trust, tailor engagement, and co-create adherence plans that reflect patients’ lived experiences and preferences. Empowering clinicians with effective, culturally sensitive strategies for patient-centered care is essential to closing gaps in PrEP uptake and achieving meaningful reductions in HIV transmission worldwide.

In the fourth activity of this CME Outfitters Snack series, expert faculty from the United States, Europe, Africa, and Asia will discuss using patient engagement and working with patients collaboratively to promote worldwide PrEP initiation and adherence strategies.


Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19453381 Mon, 06 Jul 2026 13:00:00 -0400 3684 full false Breaking Barriers to Better Hearts: Optimizing LDL-C Management for Cardiovascular Risk Reduction Breaking Barriers to Better Hearts: Optimizing LDL-C Management for Cardiovascular Risk Reduction In this CME Outfitters recorded webcast, expert faculty will review current ASCVD risk assessment guidelines, highlight the importance of achieving recommended LDL-C targets in intermediate- and high-risk patients, and discuss practical strategies to optimize therapeutic decision-making in clinical practice.

Learn More Here

]]> In this CME Outfitters recorded webcast, expert faculty will review current ASCVD risk assessment guidelines, highlight the importance of achieving recommended LDL-C targets in intermediate- and high-risk patients, and discuss practical strategies to optimize therapeutic decision-making in clinical practice.

Learn More Here

]]> CME Outfitters Medical Education Buzzsprout-19453364 Mon, 06 Jul 2026 13:00:00 -0400 3613 full false Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies Exploring the Horizons in Advanced or Recurrent Endometrial Cancer: Practical Considerations and Future Directions for New Treatment Strategies In this CE Concepts recorded webcast, expert faculty will review recent developments in the management of advanced or recurrent EC, with a focus on applying emerging clinical evidence, integrating biomarker-driven therapies, and addressing treatment-related toxicities. This program will further explore strategies to enhance interprofessional collaboration, support equitable access to molecular testing and novel therapies, and strengthen patient-centered education to optimize care delivery.

View the activity here

]]> In this CE Concepts recorded webcast, expert faculty will review recent developments in the management of advanced or recurrent EC, with a focus on applying emerging clinical evidence, integrating biomarker-driven therapies, and addressing treatment-related toxicities. This program will further explore strategies to enhance interprofessional collaboration, support equitable access to molecular testing and novel therapies, and strengthen patient-centered education to optimize care delivery.

View the activity here

]]> CME Outfitters Medical Education Buzzsprout-19397564 Wed, 24 Jun 2026 14:00:00 -0400 3887 full false A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC A CaseWise™ Webcast: From Research to Real-World: ADCs, IO Combinations, and Sequencing in Metastatic NSCLC In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.

View the activity here

]]> In this Creative Educational Concepts recorded webcast, expert faculty will delineate class-wide and agent-specific characteristics of ADCs, including mechanism of action, relevant biomarkers, efficacy, toxicity profiles, and considerations for sequencing and integration of IO therapies in biomarker-selected mNSCLC. Faculty will model evidence-based interpretation of emerging clinical trial data for TROP2-directed and other ADCs to clarify their potential role across diverse mNSCLC patient populations. By strengthening clinicians’ confidence in evidence interpretation and toxicity management, this program supports more informed and individualized treatment selection for patients with mNSCLC.

View the activity here

]]> CME Outfitters Medical Education Buzzsprout-19397543 Wed, 24 Jun 2026 14:00:00 -0400 4065 full false